Sep 21, 2023 Will the UK follow the EU’s lead in reforming product liability rules? By Harriet Hanks Andrew Austin Emma Franck-Gwinnell In summary: We recently wrote about the UK Government’s wide-ranging consultation on reforming the UK consumer product safety framework...
Aug 24, 2023 Demystifying China’s regulation of ‘human genetic resources’ By Richard Bird Ma Ya Introduction The Chinese government has regulated activities involving the use of human genetic resources (HGRs) since 1998. New...
Aug 17, 2023 CE marking recognition extended “indefinitely” for certain products – what does the future hold for UKCA marking? By Andrew Austin Emily Fowler Tom Byham On 1 August 2023, the UK Government announced an “indefinite” extension to the recognition of CE marking for certain products placed on...
Jul 27, 2023 Most recent UK Life Sciences Competitiveness Indicators highlight key areas for reform and investment By Harriet Hanks Andrew Austin Sanjana Canumalla This time last year we analysed the UK Government’s annual Life Sciences Competitiveness Indicators (LSCIs) report alongside the MHRA’s...
Jul 05, 2023 Safe harbours for R&D collaboration agreements: Quick guide to the updated EU and UK rules By Jenny Leahy Kirsty Brown Helen Panteli The European Commission’s (EC) new R&D block exemption regulation entered into force on 1 July 2023, introducing updated rules for...
Apr 06, 2023 UK government confirms plans for legislative overhaul of clinical trials regime By Harriet Hanks Beatrice Carrier In brief: The UK government has published its long-awaited response to the clinical trials reform consultation, confirming a major...
Mar 10, 2023 New UK guidance for social media content for the pharmaceutical industry By Rachel Duffy Harriet Hanks Andrew Austin At the end of January 2023, the Prescription Medicines Code of Practice Authority (PMCPA) issued its first published guidance on social...
Feb 01, 2023 Life sciences - what to expect in 2023 By Adam Golden Harriet Hanks We anticipate a year of reserved optimism in the life sciences industry for 2023. Despite uncertain financial markets and pricing...
Dec 13, 2022 The proposed revised Product Liability Directive – implications for life sciences By Rachel Duffy Andrew Austin Harriet Hanks In short: The EU’s proposed new Product Liability Directive will be particularly important for the life sciences industry. Many of the...
Nov 09, 2022 ABPI urges decisive action to rescue UK clinical trials By Beatrice Carrier Harriet Hanks Andrew Austin The Association of the British Pharmaceutical Industry (ABPI) has reported a significant decline in the number of UK industry clinical...
Oct 25, 2022 UK’s ABPI publishes updated industry guidance on working with patients and patient organisations By Beatrice Carrier Harriet Hanks Andrew Austin On 27 September 2022, the UK’s Association of the British Pharmaceutical Industry (ABPI) published its updated guidance: Working with...
Sep 28, 2022 First reaction: the proposed new Product Liability Directive is more claimant-friendly than expected By Andrew Austin In summary: This morning, the European Commission published its long-awaited proposal for a new Product Liability Directive, to govern...